* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Dounload instruction
Survey
Document related concepts
Pharmaceutical industry wikipedia , lookup
Discovery and development of cyclooxygenase 2 inhibitors wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Prescription costs wikipedia , lookup
Psychopharmacology wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Transcript
APPROVED Order of the Ministry of Health of Ukraine 17.02.2016 № 104 Registration certificate № UA/7649/02/01 INSTRUCTION for medical use NIMID® Composition: active substance: nimesulide; 1 tablet contains nimesulide 100 mg; excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, silica colloidal anhydrous. Pharmaceutical form. Tablets. General physical and chemical properties: round light-yellow tablets, smooth on both sides. Pharmacotherapeutic group. Nonsteroidal anti-inflammatory and anti-rheumatic drugs. Code АТС М01А X17. Pharmacological properties. Pharmacodynamics. Nimid® is a nonsteroidal anti-inflammatory agent of methane-sulfonanilide group which has antiinflammatory, analgesic and antipyretic effect. The therapeutic effect of Nimid is the result of its interaction with the arachidonic acid cascade and reduction of prostaglandin biosynthesis through inhibition of cyclooxygenase. Pharmacokinetics. In human body, nimesulide is quickly absorbed after oral administration and achieves the peak plasma concentrations after 2-3 hours. Up to 97.5% of nimesulide bind to plasma proteins. Nimesulide is extensively metabolized in the liver by CYP2C9, the cytochrome P450 isoenzyme. The main metabolite is a para-hydroxy derivative which also has pharmacological activity. The half-life is from 3.2 to 6 hours. Nimesulide is excreted from the organism with the urine - approximately 50% of the administered dose. About 29% of the administered dose are excreted with the feces in metabolized form. Only 1-3% is excreted unchanged from the organism. Pharmacokinetic profile in elderly patients does not change. Clinical characteristics. Indications. Treatment of acute pain, primary dysmenorrhea. Nimesulide should be used only as a second-line drug. The decision to administer nimesulide should be taken based on the assessment of all risks for the individual patient. Contraindications. Known hypersensitivity to nimesulide or any other component of the drug. History of hyperergic reactions (bronchospasm, rhinitis, urticaria) to the use of acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs. History of hepatotoxic reactions. Concomitant use of other substances with potential hepatotoxicity. Alcoholism and drug addiction. History of gastro-intestinal bleedings or perforations associated with the previous use of nonsteroidal anti-inflammatory drugs. Gastric or duodenal ulcer in the acute phase, history of and ulcer, perforation or bleeding in the digestive tract. History of cerebrovascular bleedings or other bleedings, as well as diseases accompanied by bleeding. Severe blood clotting disorders. Severe heart failure. Severe renal dysfunction. Severe hepatic dysfunction. Patients with increased body temperature and/or flu-like symptoms. Children’s age less than 12 years. III trimester of pregnancy and breast-feeding period. Interaction with other medicinal products and other forms of interaction. Pharmacodynamic interactions. Corticosteroids: increased risk of gastrointestinal ulceration or bleeding. Antiplatelet agents and selective serotonin reuptake inhibitors (SSSRIs): increased risk of bleeding in the digestive tract. Anticoagulants: NSAIDs may enhance the effects of anticoagulants such as warfarin or acetylsalicylic acid, therefore such combination is contraindicated in patients with severe coagulation disorders. If such combination therapy can not be avoided, it is necessary to carry out a careful monitoring of coagulation parameters. Diuretics, angiotensin-converting enzyme inhibitors and angiotensin II antagonists. NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. Some patients with renal dysfunction (e.g., patients with dehydration or elderly patients) the simultaneous use of ACE inhibitors, angiotensin-II antagonists or substances that inhibit cyclooxygenase system may have further impairment of renal function and occurrence of acute renal failure, which is generally reversible. These interactions should be considered when a patient uses Nimid® together with ACE inhibitors or angiotensin II antagonists. Caution should be exercised while administering this combination, especially in elderly patients. Patients should drink plenty of fluids, and renal function should be carefully monitored after the beginning of using such combination. Nimesulide temporarily reduces the effect of furosemide on the excretion of sodium and in lesser degree, on excretion of potassium, as well as reduces the diuretic effect. Concomitant administration of furosemide and Nimid® in patients with impaired renal or cardiac function requires caution. In healthy volunteers, nimesulide quickly reduces effect of furosemide aimed at excreting sodium and in a lesser extent - on potassium excretion, and also reduces the diuretic effect. Concomitant administration of nimesulide and furosemide causes a decrease (approximately 20%) of the area under the curve “concentration-time” (AUC) and reduction of furosemide cumulative excretion with unchanged renal clearance of furosemide. Pharmacokinetic interactions with other medicinal products. There were reports that NSAIDs reduces clearance of lithium resulting in increase of lithium levels in the blood plasma and toxic effects of lithium. When prescribing Nimid® in patients receiving lithium therapy lithium levels in blood plasma should be monitored closely. There is no clinically significant interaction with glibenclamide, theophylline, warfarin, digoxin, cimetidine and antacid drugs (combination of aluminum and magnesium hydroxide) in vivo. Nimesulide inhibits CYP 2C9 enzyme activity. When using the drugs that are substrates of this enzyme with Nimid®, their concentration in blood plasma may increase. Caution is necessary if nimesulide is prescribed less than 24 hours before or less than 24 hours after using methotrexate, as the serum level of the latter may grow, or its toxicity may increase. Because of the effect on renal prostaglandins, inhibitors of synthetases, which include nimesulide, may increase nephrotoxicity of cyclosporines. Effect of other drugs on nimesulide. Studies in vitro have shown that nimesulide is displaced from binding sites by tolbutamide, salicylic acid and valproic acid. Despite the fact that these interactions have been identified in plasma, these effects were not observed while the clinical use of the drug. Administration details. Adverse effects can be minimized by using the minimum effective dose during the shortest possible time period required for symptoms control. If the effect of treatment is absent (reduction of the disease symptoms), the drug therapy should be stopped. During the treatment with nimesulide, it is recommended to avoid concomitant use of hepatotoxic drugs, as well as refrain from taking alcohol. The use of nonsteroidal anti-inflammatory drugs may mask the temperature increase associated with the background bacterial infection. In case of body temperature increase or flu-like symptoms in patients using nimesulide, the drug should be stopped. Serious liver reactions, including a lethal outcome have been reported during nimesulide therapy. Patients who have symptoms similar to the symptoms of liver damage, such as anorexia, nausea, vomiting, abdominal pain, increased fatigability, dark urine, or patients whose laboratory data of liver function deviate from normal values, should stop taking the drug. Re-administration of nimesulide in such patients is contraindicated. During treatment with Nimid®, the patient should refrain from taking other analgesics. Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided. Patients using nimesulide who develop flu-like symptoms should discontinue using it. Elderly patients have an increased frequency of adverse reactions to NSAIDs; this especially refers to the possible gastrointestinal bleedings and perforations, which may lead to lethal outcome. Ulcer, bleeding or perforation of the digestive tract might endanger the patient’s life, especially if a history of the similar phenomena has been reported in a patient while using any other NSAID (no time limitation). The risk of such events increases with increased doses of NSAIDs in patients with a history of ulcers in the digestive tract especially complicated by bleeding or perforation, and in elderly patients. Such patients should initiate treatment with the lowest possible effective dose. In these patients, as well as in those, who co-administer low doses of acetylsalicylic acid or other drugs that increase the risk of gastrointestinal tract complications, the combination therapy with the protective substances, such as misoprostol or proton pump inhibitors, should be considered. Patients with toxic lesion of the digestive tract, especially elderly ones, should inform about any unusual symptoms that occur in the digestive tract, especially about bleeding. This is particularly important in the initial stages of treatment. Patients who use concomitant drugs that may increase the risk of ulcers or bleeding, such as corticosteroids, anticoagulants, selective serotonin reuptake inhibitors, antiplatelet agents (acetylsalicylic acid), should be informed about the need of caution during the use of nimesulide. In case of bleeding or gastrointestinal tract ulcers in patients who use Nimid ® the drug treatment should be discontinued. It is necessary to administer NSAIDs with caution to patients with Crohn's disease or ulcerative colitis in anamnesis, since nimesulide may aggravate them. Concomitant use of nimesulide with other drugs, such as oral contraceptives, anticoagulants, antiplatelet agents, can cause exacerbation of Crohn's disease and other diseases of the digestive tract. Patients with hypertension and/or heart failure in anamnesis, as well as those with water retention and edema due to the use of NSAIDs, require an appropriate state monitoring and a doctor’s advice. Clinical studies and epidemiological data suggest that some NSAIDs, especially at high doses and with long-term use may lead to insignificant risk of development of arterial thrombotic episodes, for example, myocardial infarction and stroke. There is no sufficient data concerning exclusion of the risk of such events occurrence during nimesulide administration. Nimesulide should be administered to patients with uncontrolled arterial hypertension, acute cardiac insufficiency, known coronary heart disease, peripheral arterial disease and/or cerebrovascular disease only after a precise assessment of their states. This also applies to patients with risk factors for cardiovascular disease, such as hypertension, hyperlipidemia, diabetes and smoking The drug should be administered to patients with renal dysfunction or heart failure with caution due to possible worsening of renal functions. In case of recrudescence, the treatment should be stopped Elderly patients should be carefully monitored due to possible development of bleeding and perforation of the digestive tract, renal, liver or heart impairment. Since nimesulide may affect platelet function, it should be administered with caution in patients with hemorrhagic diathesis. However, nimesulide does not substitute acetylsalicylic acid in cardiovascular disease prevention Rare cases of severe skin reactions, some of which can be deathful, e.g. exfoliative dermatitis, StevensJohnson syndrome, toxic epidermal necrosis, have been reported while using NSAIDs. In most cases, if during the first month of the earlier course of treatment, these reactions occurred, the risk of their occurrence in patients significantly increases. Nimid® should be withdrawn when the first signs of skin rash, mucous membranes lesions and other phenomena of allergic reaction occur. Use during pregnancy or breast-feeding. Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or fetal development. The epidemiological studies suggest that the use of drugs that inhibit prostaglandin synthesis in early pregnancy may increase the risk of spontaneous abortion, the occurrence of fetal heart defects and gastroschisis. The absolute risk of the cardiovascular system abnormalities increased from less than 1% to about 1.5%. It is considered that the risk increases with increasing dose and duration of use. Nimesulide administration is not recommended in I and II trimesters of pregnancy, unless it is absolutely necessary. In the case of the drug administration in women who are trying to become pregnant, or in the I and II trimesters of pregnancy, the smallest possible dose and the least possible duration of treatment should be chosen. During the III trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to the development of: • cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); • renal dysfunction, which may progress to renal failure with oligoamnios. The mother and the fetus at the end of pregnancy may have: • prolongation of bleeding time, antiaggregatory effect that can occur even when using very low doses; • inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, nimesulide is contraindicated during the III trimester of pregnancy. As other NSAIDs that inhibit prostaglandin synthesis, nimesulide may cause premature closure of the ductus arteriosus, pulmonary hypertension, oliguria, oligoamnios. The risk of bleeding, uterine inertia and peripheral edema. There are several reports of renal failure in infants whose mothers used nimesulide in late pregnancy. Animal studies have shown atypical reproductive toxicity of the drug, but there are no reliable data on nimesulide administration in pregnant women. The potential rick for humans is not defined, therefore, it is not recommended to prescribe nimesulide during the I and II trimester of pregnancy. Since it is unknown whether nimesulide penetrates into the breast milk, its use is contraindicated during breast-feeding. Nimesulide may impair female fertility, therefore it is not recommended for use in women attempting to conceive. Women having problems with getting pregnant or undergoing examination for infertility should consider stopping the administration of nimesulide. If pregnancy is detected during nimesulide administration, the doctor should be informed about it. Effects on ability to drive and operate machinery. No studies on the effect of nimesulide on the ability to drive motor transport or operate other mechanisms have been performed, but if while using nimesulide, the patients had headache, dizziness or somnolence, they should not drive motor transport or work with other mechanisms. Administration and dosage. To minimize the possible adverse effects, the minimum effective dose should be used for the shortest time. It is recommended to use the drug after meal with sufficient quantity of liquid. Maximum duration of treatment with Nimid is 15 days. Adults. 1 tablet (100 mg) 2 times per day. Elderly patients. No dosage adjustment is required. Children aged from 12 years. No dosage adjustment is required. Patients with impaired renal function. In patients with mild or moderate renal impairment (creatinine clearance is 30-80 ml/min), dosage adjustment is not required, while severe renal impairment (creatinine clearance <30 ml/h) is a contraindication for administration of Nimid®. Children. Nimid® is contraindicated in children aged less than 12 years. Overdose. The symptoms of acute overdose with nonsteroidal anti-inflammatory drugs (NSAIDs) are usually limited to such ones: lethargy, somnolence, vomiting epigastric pain. These symptoms as a rule are reversible with supportive treatment. Gastrointestinal bleeding, arterial hypertension, acute renal failure, respiratory depression, coma are possible, however, such phenomena are rare. Anaphylactoid reactions have been reported when using therapeutic doses of NDAIDs and when overdose. There is no specific antidote. The treatment of overdose is symptomatic and supportive. There are no data on excretion of nimesulide with hemodialysis, but if keeping in mind the high degree of binding of nimesulide to the plasma proteins (up to 97.5%); it is unlikely that the dialysis will be effective. If there are symptoms of overdose or after using a high dose of the drug, within 4 hours after the intake the patients may be prescribed: induction of vomiting and/or taking activated carbon (60-100 g for adults) and/or osmotic laxative. Forced diuresis, increasing alkalinity of the urine and hemoperfusion may be ineffective due to the high degree of binding of nimesulide with blood plasma proteins. The renal and hepatic functions should be controlled. Adverse reactions. Blood and lymphatic system disorders: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura. Immune system disorders: hypersensitivity, anaphylaxis. Metabolic disorders: hyperkalemia. Mental disorders: feeling of fear, nervousness, nightmares. Nervous system disorders: dizziness, headache, somnolence, encephalopathy (Reye's syndrome). Vision disorders: blurred vision, visual disturbances. Ear and equilibration disorders: vertigo (dizziness). Cardiovascular system disorders: tachycardia, hemorrhage, blood pressure lability, flushes, arterial hypertension, increased risk of arterial thrombotic complications, such as myocardial infarction or stroke, heart failure. Respiratory system: dyspnea, asthma, bronchospasm. Gastrointestinal tract disorders: diarrhea, nausea, vomiting, including vomiting blood, constipation, flatulence, gastritis, abdominal pain, dyspepsia, stomatitis, black stool, gastrointestinal bleeding, gastric/duodenal ulceration and perforation, recrudescence of colitis and Crohn's disease. Hepatobiliary system disorders: hepatitis, fulminant (instant) hepatitis with fatal outcome, including jaundice, cholestasis. Skin disorders: pruritus, skin rash, increased sweating, erythema, dermatitis, urticaria, angioedema, face edema, erythema multiform, Stevens–Johnson syndrome, toxic epidermal necrolysis. Urinary system disorders: dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis. General disorders: swelling, weakness, asthenia, hypothermia. Laboratory data: increase in liver enzymes. Shelf-life. 3 years. Storage conditions. Store at the temperature not more than 25 °С in the original package. Keep it out of reach of children. Package. 10 tablets are in a blister, 1 blister is in a carton package №10 (10х1). 10 tablets are in a blister, 1 blister is in a carton package, 10 packages are in a box №100 (10×1×10). Conditions of supply. By prescription. Manufacturer. KUSUM HEALTHCARE PVT LTD. Address. SP-289 (A), RIICO Industrial area, Chopanki, Bhiwadi, Dist. Alwar (Rajasthan), India. Date of last revision.